Daily Watch List: Fibrocell Science (NASDAQ:FCSC), Luxoft Holding (NYSE:LXFT), Lipocine (NASDAQ:LPCN), Capricor Therapeutics (NASDAQ:CAPR)

Capital One Financial Corporation (NYSE:COF) shares advanced 1.29% in last trading session and ended the day at $75.96. COF has a return on assets of 1.20%. Capital One Financial Corporation (NYSE:COF) quarterly performance is 26.62%.

Capital One Financial (NYSE: COF) reported Q1 EPS of $1.84, $0.07 worse than the analyst estimate of $1.91. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.16 billion.

Fibrocell Science, Inc. (NASDAQ:FCSC) ended the last trading day at $3.12. Company weekly volatility is calculated as 16.06% and price to cash ratio as 4.68. Fibrocell Science, Inc. (NASDAQ:FCSC) showed a weekly performance of 19.08%.

Fibrocell Science (NASDAQ: FCSC) announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for FCX-013 for the treatment of localized scleroderma, a chronic autoimmune disease characterized by thickening of the skin and connective tissue that can be debilitating and painful.

On 26 April, Luxoft Holding, Inc. (NYSE:LXFT) shares advanced 3.93% and was closed at $60.54. LXFT EPS growth in last 5 year was 30.08%. Luxoft Holding, Inc. (NYSE:LXFT) year to date (YTD) performance is -21.51%.

Luxoft Holding, Inc (NYSE:LXFT), a leading provider of software development services and innovative IT solutions to a global client base, will announce its financial results for the fourth quarter and full year ended March 31, 2016 on Thursday, May 12, 2016 after market close.

Lipocine Inc. (NASDAQ:LPCN) shares fell -7.35% in last trading session and ended the day at $10.21. LPCN has a return on assets of -42.20%. Lipocine Inc. (NASDAQ:LPCN) quarterly performance is 8.39%.

Lipocine Inc. (NASDAQ:LPCN), announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, presented a company overview at Needham & Company’s 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. ET.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) caters to the Healthcare space. Its weekly performance is 13.77%. On the last day of trading company shares ended up at $3.80.

Gregory W. Schafer, a member of the Board of Directors of Capricor Therapeutics, Inc. (NASDAQ:CAPR), has notified the Company that he will not stand for re-election when his term on the Board expires at the Company’s 2016 Annual Meeting of Stockholders, which is scheduled for June 2, 2016 (the “Annual Meeting”). Mr. Schafer will continue to serve as a member of the Board, as the Chairman of the Audit Committee of the Board (the “Audit Committee”) and as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) until the Annual Meeting.